EA201790170A1 - Терапевтические соединения-ингибиторы - Google Patents
Терапевтические соединения-ингибиторыInfo
- Publication number
- EA201790170A1 EA201790170A1 EA201790170A EA201790170A EA201790170A1 EA 201790170 A1 EA201790170 A1 EA 201790170A1 EA 201790170 A EA201790170 A EA 201790170A EA 201790170 A EA201790170 A EA 201790170A EA 201790170 A1 EA201790170 A1 EA 201790170A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- therapeutic compounds
- compounds
- compounds inhibitors
- useful
- plasma kallikrein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
В настоящей заявке раскрыты гетероциклические соединения и фармацевтические композиции, содержащие указанные соединения, которые являются полезными для ингибирования калликреина плазмы. Кроме того, заявленные соединения и композиции полезны для лечения заболеваний, которые связаны с ингибированием калликреина плазмы, такие как ангионевротический отек и тому подобное.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462025203P | 2014-07-16 | 2014-07-16 | |
PCT/US2014/072851 WO2015103317A1 (en) | 2013-12-30 | 2014-12-30 | Therapeutic inhibitory compounds |
US201562187786P | 2015-07-01 | 2015-07-01 | |
US201562190223P | 2015-07-08 | 2015-07-08 | |
PCT/US2015/040659 WO2016011209A1 (en) | 2014-07-16 | 2015-07-15 | Therapeutic inhibitory compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201790170A1 true EA201790170A1 (ru) | 2017-08-31 |
EA035410B1 EA035410B1 (ru) | 2020-06-09 |
Family
ID=55079038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201790170A EA035410B1 (ru) | 2014-07-16 | 2015-07-15 | Терапевтические соединения-ингибиторы |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3169325B1 (ru) |
JP (2) | JP6951970B2 (ru) |
KR (1) | KR102286305B1 (ru) |
CN (1) | CN107072985B (ru) |
AU (1) | AU2015289643B2 (ru) |
BR (1) | BR112017000816A2 (ru) |
CA (1) | CA2954814A1 (ru) |
EA (1) | EA035410B1 (ru) |
MX (1) | MX2017000450A (ru) |
WO (1) | WO2016011209A1 (ru) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6527147B2 (ja) | 2013-08-14 | 2019-06-05 | カルヴィスタ ファーマシューティカルズ リミテッド | 血漿カリクレインの阻害薬 |
TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
JP6759100B2 (ja) * | 2013-12-30 | 2020-09-23 | ライフサイ ファーマシューティカルズ,インク. | 治療用阻害化合物 |
US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
CN107072985B (zh) * | 2014-07-16 | 2020-02-07 | 莱福斯希医药公司 | 治疗性抑制化合物 |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
LT3464271T (lt) | 2016-05-31 | 2020-09-10 | Kalvista Pharmaceuticals Limited | Pirazolo dariniai kaip plazmos kalikreino inhibitoriai |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
GB201703282D0 (en) * | 2017-03-01 | 2017-04-12 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compounds |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
IL274557B2 (en) | 2017-11-29 | 2024-09-01 | Kalvista Pharmaceuticals Ltd | Dosage forms containing a plasma kallikrein inhibitor |
US20200405708A1 (en) * | 2018-02-28 | 2020-12-31 | Attune Pharmaceuticals, Inc. | Treatment of hereditary angioedema |
US10730874B2 (en) | 2018-03-13 | 2020-08-04 | Shire Human Genetic Therapies, Inc. | Inhibitors of plasma kallikrein and uses thereof |
CN110256342B (zh) * | 2019-07-16 | 2022-06-07 | 河南省科学院化学研究所有限公司 | 一种2-氰基喹啉衍生物的合成方法 |
EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
JP2022549601A (ja) | 2019-09-18 | 2022-11-28 | 武田薬品工業株式会社 | ヘテロアリール血漿カリクレインインヒビター |
PT4031547T (pt) | 2019-09-18 | 2024-08-27 | Takeda Pharmaceuticals Co | Inibidores de calicreína plasmática e utilizações dos mesmos |
BR112022010924A2 (pt) | 2019-12-06 | 2022-09-06 | Vertex Pharma | Tetra-hidrofuranos substituídos como moduladores de canais de sódio |
WO2022220608A1 (ko) * | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 |
US20240228441A1 (en) * | 2021-04-14 | 2024-07-11 | Lg Chem, Ltd. | Method for preparing intermediate for synthesis of sphingosine-1-phosphate receptor agonist |
PE20241335A1 (es) | 2021-06-04 | 2024-07-03 | Vertex Pharma | N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio |
WO2024059186A1 (en) * | 2022-09-15 | 2024-03-21 | Takeda Pharmaceutical Company Limited | N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0226990B1 (en) * | 1985-12-16 | 1990-03-14 | EASTMAN KODAK COMPANY (a New Jersey corporation) | Envelopes constructed for ink jet printing |
WO2005074513A2 (en) * | 2004-01-30 | 2005-08-18 | Merck & Co., Inc. | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integrase inhibitors |
GB0403155D0 (en) * | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
US20070254894A1 (en) * | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
CA2637620A1 (en) * | 2006-02-16 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
JP2010513231A (ja) * | 2006-12-14 | 2010-04-30 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | たんぱく質キナーゼインヒビターとして有用なジヒドロピリジン誘導体 |
WO2009083553A1 (en) * | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Azine compounds as glucokinase activators |
JPWO2009119088A1 (ja) * | 2008-03-25 | 2011-07-21 | 武田薬品工業株式会社 | 複素環化合物 |
AU2009272486A1 (en) * | 2008-07-18 | 2010-01-21 | Takeda Pharmaceutical Company Limited. | Benzazepine derivatives and their use as hstamine H3 antagonists |
US9290485B2 (en) * | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
WO2013111108A1 (en) * | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
JP6280132B2 (ja) * | 2012-12-07 | 2018-02-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Cb2アゴニストとして有用なピリジン−2−アミド |
JP6527147B2 (ja) * | 2013-08-14 | 2019-06-05 | カルヴィスタ ファーマシューティカルズ リミテッド | 血漿カリクレインの阻害薬 |
US20160273953A1 (en) * | 2013-12-16 | 2016-09-22 | Beko Technologies Gmbh | Method for monitoring the filling level in a collection chamber, and monitoring arrangement |
JP6759100B2 (ja) * | 2013-12-30 | 2020-09-23 | ライフサイ ファーマシューティカルズ,インク. | 治療用阻害化合物 |
CN107072985B (zh) * | 2014-07-16 | 2020-02-07 | 莱福斯希医药公司 | 治疗性抑制化合物 |
-
2015
- 2015-07-15 CN CN201580049953.XA patent/CN107072985B/zh not_active Expired - Fee Related
- 2015-07-15 EA EA201790170A patent/EA035410B1/ru unknown
- 2015-07-15 MX MX2017000450A patent/MX2017000450A/es unknown
- 2015-07-15 WO PCT/US2015/040659 patent/WO2016011209A1/en active Application Filing
- 2015-07-15 CA CA2954814A patent/CA2954814A1/en not_active Abandoned
- 2015-07-15 AU AU2015289643A patent/AU2015289643B2/en not_active Ceased
- 2015-07-15 JP JP2017501403A patent/JP6951970B2/ja active Active
- 2015-07-15 EP EP15822307.3A patent/EP3169325B1/en active Active
- 2015-07-15 KR KR1020177004192A patent/KR102286305B1/ko active IP Right Grant
- 2015-07-15 BR BR112017000816A patent/BR112017000816A2/pt not_active Application Discontinuation
-
2020
- 2020-05-14 JP JP2020085352A patent/JP6982343B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
WO2016011209A1 (en) | 2016-01-21 |
JP2017520597A (ja) | 2017-07-27 |
EP3169325A4 (en) | 2018-04-11 |
KR102286305B1 (ko) | 2021-08-09 |
CN107072985B (zh) | 2020-02-07 |
CA2954814A1 (en) | 2016-01-21 |
AU2015289643B2 (en) | 2020-10-22 |
CN107072985A (zh) | 2017-08-18 |
JP2020147575A (ja) | 2020-09-17 |
AU2015289643A1 (en) | 2017-03-02 |
EP3169325A1 (en) | 2017-05-24 |
EA035410B1 (ru) | 2020-06-09 |
MX2017000450A (es) | 2017-08-16 |
EP3169325B1 (en) | 2021-04-28 |
BR112017000816A2 (pt) | 2017-12-05 |
JP6982343B2 (ja) | 2021-12-17 |
JP6951970B2 (ja) | 2021-10-20 |
KR20170034902A (ko) | 2017-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201790170A1 (ru) | Терапевтические соединения-ингибиторы | |
EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
PH12018500899A1 (en) | Compositions and methods for inhibiting arginase activity | |
PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
EA201691421A1 (ru) | Гетероарилы и их применение | |
NZ729005A (en) | Aminopyrimidinyl compounds as jak inhibitors | |
EA201591509A1 (ru) | Ингибиторы cdc7 | |
MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
EA201790376A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
EA201790082A1 (ru) | Ингибиторы лизин-специфической демитилазы-1 | |
WO2017001926A3 (en) | Therapeutic inhibitory compounds | |
WO2017001936A3 (en) | Therapeutic inhibitory compounds | |
EA201790085A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
MX2017011000A (es) | Compuestos de pirazol sustituidos como inhibidores de serina proteasa. | |
EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
EA201692091A1 (ru) | Хиноксалиновые соединения и их применение | |
EA201890364A1 (ru) | СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
EA201790156A1 (ru) | Азетидинилоксифенилпирролидиновые соединения | |
CR20170426A (es) | Inhibidores de bace 1 | |
MX2019005294A (es) | Inhibidores de las interacciones de mtor-deptor y metodos de uso de los mismos. | |
PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases |